Holmusk, the company behind diabetes tracker app GlycoLeap, plans to use the new funding to support its expansion in US and Europe

Singapore-based digital health and data analytics startup Holmusk announced on Tuesday that it has raised a US$9.75 million pre-Series A funding round by Heritas Venture Fund, with participation from undisclosed new and existing investors.

Already having a presence in Malaysia, UK, and US, Holmusk plans to use the new funding to support its expansion in US and Europe.

“Holmusk’s focus on promoting healthy lifestyles and addressing chronic disease management made this an exciting opportunity to be a part of,” said Chik Wai Chiew, CEO of Heritas Capital Management which oversees Heritas Venture Fund, commenting on the investment.

“Its approach of combining deep analytics with clinical research and real-world data is promising and we are pleased to see the company on track to build upon the successes of GlycoLeap and SuperLeap and develop next generation versions in 2019.”

Also Read: Holmusk, makes the fight against diabetes a less lonely battle

Holmusk is the company behind GlycoLeap and SuperLeap, which help patients with chronic diseases such as diabetes manage their illness through features such as blood sugar level, weight, and diet tracker.

In 2016, the company announced that it has acquired rights to Duke University School of Medicine’s behavioural health EHR platform MindLinc.

With the acquisition, the startup claimed to hold one of the largest behavioral health databases in the world.

It is currently developing MindLinc 2.0 which will include predictive disease models based on longitudinal patient data.

Holmusk CEO and Co-Founder Nawal Roy spoke to e27 about the company’s fundraising plan at the Echelon Asia Summit 2017.

By the time the company was raising US$6 million with the goal to expand to China, Japan, India, and Indonesia.

The post Healthtech startup Holmusk raises US$9.75M pre-Series A by Heritas Venture Fund appeared first on e27.